(RTTNews) - Wave Life Sciences Ltd. (WVE), a clinical-stage biotechnology company, Tuesday announced positive interim data from the Phase 2 FORWARD-53 study evaluating WVE-N531 in boys with Duchenne ...
Results that may be inaccessible to you are currently showing.